Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.

Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.

Eur Urol. 2019 Jan 24. pii: S0302-2838(18)31044-3. doi: 10.1016/j.eururo.2018.12.036. [Epub ahead of print]

PMID:
30685078
2.

Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?

Hoffmann R, Logan C, O'Callaghan M, Gormly K, Chan K, Foreman D.

Int Urol Nephrol. 2018 Jan;50(1):13-19. doi: 10.1007/s11255-017-1753-1. Epub 2017 Nov 29.

PMID:
29188489
4.

Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.

Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker ER, Lu DSK, Reiter RE.

Eur Urol. 2019 May;75(5):712-720. doi: 10.1016/j.eururo.2018.11.031. Epub 2018 Dec 1.

PMID:
30509763
5.

The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer.

Zhao C, Gao G, Fang D, Li F, Yang X, Wang H, He Q, Wang X.

Clin Imaging. 2016 Sep-Oct;40(5):885-8. doi: 10.1016/j.clinimag.2016.04.010. Epub 2016 Apr 26.

PMID:
27179959
6.

Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?

Sanguedolce F, Petralia G, Sokhi H, Tagliabue E, Anyamene N, Hellawell G, Padhani AR.

Clin Genitourin Cancer. 2018 Apr;16(2):155-163.e6. doi: 10.1016/j.clgc.2017.10.020. Epub 2017 Nov 21.

PMID:
29198639
7.

Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50.

Gielchinsky I, Scheltema MJ, Cusick T, Chang J, Shnier R, Moses D, Delprado W, Nguyen Q, Yuen C, Haynes AM, Stricker PD.

Res Rep Urol. 2018 Oct 4;10:145-150. doi: 10.2147/RRU.S169017. eCollection 2018.

8.

Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.

Luzzago S, Musi G, Catellani M, Russo A, Di Trapani E, Mistretta FA, Bianchi R, Cozzi G, Conti A, Pricolo P, Ferro M, Matei DV, Mirone V, Petralia G, de Cobelli O.

Urol Int. 2018;101(1):56-64. doi: 10.1159/000488772. Epub 2018 May 7.

PMID:
29734177
9.

Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

An JY, Sidana A, Choyke PL, Wood BJ, Pinto PA, Türkbey İB.

Balkan Med J. 2017 Sep 29;34(5):388-396. doi: 10.4274/balkanmedj.2017.0708.

10.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
11.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.

BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.

12.

Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.

Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E.

Eur Urol Oncol. 2019 Feb;2(1):1-11. doi: 10.1016/j.euo.2018.08.005. Epub 2018 Sep 5.

PMID:
30929837
13.

A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.

Giannarini G, Girometti R, Crestani A, Rossanese M, Calandriello M, Cereser L, Bednarova S, Battistella C, Sioletic S, Zuiani C, Valotto C, Ficarra V.

Urology. 2019 Jan;123:191-197. doi: 10.1016/j.urology.2018.07.067. Epub 2018 Sep 28.

PMID:
30273613
14.

Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.

Rastinehad AR, Waingankar N, Turkbey B, Yaskiv O, Sonstegard AM, Fakhoury M, Olsson CA, Siegel DN, Choyke PL, Ben-Levi E, Villani R.

PLoS One. 2015 Nov 25;10(11):e0143404. doi: 10.1371/journal.pone.0143404. eCollection 2015.

15.

Central zone lesions on magnetic resonance imaging: Should we be concerned?

Tan WP, Mazzone A, Shors S, Antoine N, Ekbal S, Khare N, McKiel C, Pessis D, Deane L.

Urol Oncol. 2017 Jan;35(1):31.e7-31.e12. doi: 10.1016/j.urolonc.2016.08.006. Epub 2016 Sep 28.

PMID:
27692837
16.

The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.

Wang X, Bao J, Ping X, Hu C, Hou J, Dong F, Guo L.

Oncol Lett. 2018 Sep;16(3):3201-3206. doi: 10.3892/ol.2018.9038. Epub 2018 Jun 28.

17.

Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.

Curci NE, Lane BR, Shankar PR, Noyes SL, Moriarty AK, Kubat A, Brede C, Montgomery JS, Auffenberg GB, Miller DC, Montie JE, George AK, Davenport MS.

Urology. 2018 Jun;116:137-143. doi: 10.1016/j.urology.2018.02.043. Epub 2018 Apr 10.

PMID:
29653121
18.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
19.

Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review.

Gómez Rivas J, Giganti F, Álvarez-Maestro M, Freire MJ, Kasivisvanathan V, Martinez-Piñeiro L, Emberton M.

Eur Urol Focus. 2018 Mar 7. pii: S2405-4569(18)30074-9. doi: 10.1016/j.euf.2018.02.012. [Epub ahead of print] Review.

PMID:
29525382
20.

Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.

Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, Popeneciu IV, Huettenbrink C, Gasch C, Klein T, Bonekamp D, Duensing S, Roth W, Schueler S, Stock C, Schlemmer HP, Roethke M, Hohenfellner M, Hadaschik BA.

Eur Urol. 2016 Nov;70(5):846-853. doi: 10.1016/j.eururo.2015.12.052. Epub 2016 Jan 19.

PMID:
26810346

Supplemental Content

Support Center